GH•benzinga•
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Summary
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC detection and compliance, potentially extending patient survival.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga